Literature DB >> 24900737

Design, synthesis, and evaluation of prodrugs of ertapenem.

Sheo B Singh1, Diane Rindgen1, Prudence Bradley1, Lovji Cama1, Wanying Sun1, Michael J Hafey1, Takao Suzuki2, Nengxue Wang2, Hao Wu2, Basheng Zhang2, Li Wang2, Chongmin Ji2, Hongshi Yu2, Richard Soll2, David B Olsen3, Peter T Meinke1, Deborah A Nicoll-Griffith1.   

Abstract

Carbapenems are intravenous lifesaving hospital antibiotics. Once patients leave the hospital, they are sent home with antibiotics other than carbapenems since they cannot be administered orally due to lack of oral absorption primarily because of very highly polarity. A prodrug approach is a bona fide strategy to improve oral absorption of compounds. Design and synthesis, in vitro and in vivo evaluation of diversified prodrugs of ertapenem, one of the only once daily dosed carbapenems is described. Many of the prodrugs prepared for evaluation are rapidly hydrolyzed in rat plasma. Only bis-(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl (medoxomil) ester prodrug was rapidly hydrolyzed in most of the plasmas including rat, human, dog, and monkey. Although the rate of conversion of ertapenem diethyl ester prodrug (6) was slow in in vitro plasma hydrolysis, it showed the best in vivo pharmacokinetic profile in dog by an intraduodenal dosing giving >31% total oral absorption.

Entities:  

Keywords:  Ertapenem; antibiotics; carbapenem; ertapenem bis-lactone; ertapenem bis-pivoxyl; ertapenem diethyl ester; intraduodenal dosing; prodrugs

Year:  2013        PMID: 24900737      PMCID: PMC4027230          DOI: 10.1021/ml400092n

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.345


  15 in total

Review 1.  Xemilofiban/orbofiban: insight into drug development.

Authors:  R Anders; J Kleiman; N Nicholson; B Wazowicz; D Burns
Journal:  Cardiovasc Drug Rev       Date:  2001

2.  In vitro activity of ertapenem against common clinical isolates in relation to human pharmacokinetics.

Authors:  I Friedland; L A Mixson; A Majumdar; M Motyl; G L Woods
Journal:  J Chemother       Date:  2002-10       Impact factor: 1.714

3.  Prodrugs: Some thoughts and current issues.

Authors:  Valentino J Stella
Journal:  J Pharm Sci       Date:  2010-12       Impact factor: 3.534

4.  Effects of the quantity of water and milk ingested concomitantly with AS-924, a novel ester-type cephem antibiotic, on its pharmacokinetics.

Authors:  F Matsumoto; I Sakurai; M Morita; T Takahashi; N Mori; T Sugihara; A Sakai; S Yamaji; Y Akaike; K Yano
Journal:  Int J Antimicrob Agents       Date:  2001-11       Impact factor: 5.283

5.  Butyrylcholinesterase, paraoxonase, and albumin esterase, but not carboxylesterase, are present in human plasma.

Authors:  Bin Li; Meghan Sedlacek; Indumathi Manoharan; Rathnam Boopathy; Ellen G Duysen; Patrick Masson; Oksana Lockridge
Journal:  Biochem Pharmacol       Date:  2005-10-06       Impact factor: 5.858

6.  Design, synthesis, bioconversion, and pharmacokinetics evaluation of new ester prodrugs of olmesartan.

Authors:  Jeong-Soo Chang; Mohammed I El-Gamal; Woong San Lee; Hanan S Anbar; Hye Jin Chung; Hyun-Il Kim; Young-Jin Cho; Bong Sang Lee; Sun Ahe Lee; Ji Yun Moon; Dong Jin Lee; Hong-Ryeol Jeon; Jaehwi Lee; Young Wook Choi; Chang-Hyun Oh
Journal:  Eur J Med Chem       Date:  2011-05-13       Impact factor: 6.514

Review 7.  Pharmacokinetics of oral cefetamet pivoxil (Ro 15-8075) and intravenous cefetamet (Ro 15-8074) in humans: a review.

Authors:  K Stoeckel; Y K Tam; J Kneer
Journal:  Curr Med Res Opin       Date:  1989       Impact factor: 2.580

Review 8.  Lovastatin: a new cholesterol-lowering agent.

Authors:  J J Krukemyer; R L Talbert
Journal:  Pharmacotherapy       Date:  1987       Impact factor: 4.705

9.  Pharmacokinetics of ertapenem in healthy young volunteers.

Authors:  A K Majumdar; D G Musson; K L Birk; C J Kitchen; S Holland; J McCrea; G Mistry; M Hesney; L Xi; S X Li; R Haesen; R A Blum; R L Lins; H Greenberg; S Waldman; P Deutsch; J D Rogers
Journal:  Antimicrob Agents Chemother       Date:  2002-11       Impact factor: 5.191

Review 10.  Comparative review of the carbapenems.

Authors:  George G Zhanel; Ryan Wiebe; Leanne Dilay; Kristjan Thomson; Ethan Rubinstein; Daryl J Hoban; Ayman M Noreddin; James A Karlowsky
Journal:  Drugs       Date:  2007       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.